Oct 28 2009
Excelimmune, Inc. (www.excelimmune.com) announced today that the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant to support research aimed at developing new treatments for Clostridium difficile (C. difficile) infection, employing Excelimmune’s expertise in developing novel antibody therapies for human disease. The SBIR grant will fund a project entitled “The Creation of a Human Recombinant Polyclonal Antibody Therapy against C. difficile,” which will be conducted at Excelimmune’s new facility in Woburn, MA and in consortium with the Roger Williams Medical Center in Providence, RI.
“This grant is an important milestone for our company,” said Quinton Zondervan, President and CEO of Excelimmune. “The support from the NIH will allow us to expand and accelerate our development program focused on using human recombinant polyclonal antibodies to fight infectious disease.”
Excelimmune has developed a novel platform for the creation of human recombinant polyclonal antibodies. Using this platform, Excelimmune is targeting bacterial pathogens that cause disease, including C. difficile.
SOURCE Excelimmune
BMI's influence on disease pathogenesis uncovered in new research